Vosevi for hepatitis C patients who didn't get better with past antiviral treatment
Part of Digestive system, Infections clinical trials.
This trial tests if Vosevi (a combination of three antiviral drugs) can clear the hepatitis C virus in people who have already tried standard antiviral treatment but still have the virus. It also compares this to another treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 70 years old.
- You have taken standard antiviral medication for hepatitis C before (called DAA therapy).
- Your hepatitis C virus is still present after that treatment (HCV-RNA positive).
- You are willing to take a daily oral medication for the study.
- You can follow the study instructions and take your medication as directed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests hepatitis C virus (HCV) treatment using medications called sofosbuvir and velpatasvir, with the goal of curing the infection. If you've been treated before and the virus came back, you may be eligible for retreatment with additional medication.
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
This study offers a once-daily pill (Epclusa) to treat hepatitis C for people in jail who have never taken HCV medicine before. The goal is to see if starting treatment while incarcerated and continuing after release can cure the infection.
This study compares two ways to treat hepatitis C: getting treatment at a local clinic near you, or the usual care at a central hospital. It aims to see if treatment at local clinics is safe, effective, and more convenient for patients.
This trial looks at how two hepatitis C treatments (GLE/PIB or SOF/VEL) interact with other drugs or recreational substances. It may help doctors understand how to better manage treatment for people taking multiple medications.
Hear when a new Chronic Hepatitis C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.